Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer

Cheryl Lai, Acting Deputy Editor of The Lancet Oncology, is joined by Professor Fred Saad (Department of Surgery/Urology, University of Montreal, Montreal, QC, Canada) to discuss pain and health-related quality-of-life outcomes from the randomised phase 3 ARANOTE trial of darolutamide in metastatic hormone-sensitive prostate cancer. Hear about the findings from the study, the importance of quality of life for patients with metastatic prostate cancer, and how clinical research in metastatic hormone-sensitive prostate cancer might look in the next 5 years.

Read the full article: thelancet.com/journals/lanonc/article/PIIS1470…)00014-8/fulltext?dgcid=podcast_acq-april-26_lanonc